Asia Pacific Protein Expression Market Key Players and Forecast by 2028

The protein expression market in Asia Pacific is expected to grow from US$ 461.2 million in 2021 to US$ 869.7 million by 2028; it is estimated to grow at a CAGR of 9.5% from 2021 to 2028.

In November 2018, Stilla Technologies announced the completion of a Series A financing round of US$ 18.3 million (€16 million) led by Illumina Ventures. The company will use the funds to commercialize its Naica digital PCR system and develop clinical applications. Further, in April 2020, MedGenome, a Bengaluru-headquartered genetic diagnostics, research, and data company, announced that it had raised US$ 55 million (about INR 419 crore) in a new round of funding, led by LeapFrog Investments, a global impact investment firm. Also, MedGenome claims to have built the largest database of South Asian genetic variants in genetic diagnostics in India and research partnerships. It has completed over 200,000 genomic tests to date and by obtaining samples from more than 550 hospitals and 6,000 clinics across India. Thus, the continuous funding by the manufacturers and governments in genomics and proteomics is expected to create lucrative opportunities for the growth of the protein expression market in the coming years.

The current COVID-19 pandemic has produced a huge immediate demand for SARS-CoV-2 RNA/protein-based diagnostic reagents and associated antibodies, putting tremendous strain on the supply and distribution chain. By achieving rapid, larger-scale production, complemented by long-term higher volume production in transgenic plants, transient expression in plants may resolve the shortage. For example, on Dec. 2020, Clover Biopharmaceuticals, a China-based biotechnology company, announced positive clinical data from its Phase 1 trial demonstrating that its protein-based COVID-19 S-Trimer vaccine candidates in combination with adjuvants from either GSK induce strong immune responses, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in 150 adult and elderly participants. However, in long run the market has strong potential to boost the growth rate as Asia Pacific is most populated region in the world and where high number of Covid 19 cases detected. Also, the prevalence of other infectious diseases and cancer cases.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the protein expression market. The Asia Pacific protein expression market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Protein Expression Market Segmentation     

By Product

• Competent Cells
• Expression Vectors
• Reagents
• Instruments

By Services

• Antibody Development & Production
• Protein Expression & Production
• Hybridoma One-Stop Services
• Stable Cell Line Development
• Bioanalytical Assay Services

By Application

• Research
• Therapeutic
• Industrial

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutes
• Others

By Country

• Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

Companies Mentioned

• Thermo Fisher Scientific Inc.
• GenScript
• Merck KGaA
• Agilent Technologies, Inc.
• Takara Bio Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN
• New England Biolabs
• Promega Corporation

Asia Pacific Protein Expression Report Scope